RxDoctor Payments Data

Antoine Kassis, MD

Internal Medicine · Jacksonville, FLNPI 1477627875

Payments from drug & device makers

$2,916in general payments, 2019–2025

Across 164 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$801
  • Novo Nordisk$307
  • Bayer$267
  • Boehringer Ingelheim$259
  • Pfizer$201
  • Lilly USA, LLC$171
  • plus $909 from 21 others

What the payments were for

  • Food & beverage$2,88999%
  • Education$281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,916 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$219,515
Medicare patients
180
Services billed
3,113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide260$283,440
EliquisApixaban144$150,531
JardianceEmpagliflozin130$139,053
FarxigaDapagliflozin Propanediol76$74,618
JanuviaSitagliptin Phosphate68$73,788
MounjaroTirzepatide48$53,132
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$37,762
EntrestoSacubitril/Valsartan25$25,225
LinzessLinaclotide21$23,666
Diclofenac Sodium120$15,668
XareltoRivaroxaban11$14,357
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen256$7,342
Albuterol Sulfate HfaAlbuterol Sulfate152$5,373
Gabapentin301$5,037
Atorvastatin Calcium558$4,840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$307$283,440260 claims
PfizerEliquis$201$150,531144 claims
Boehringer IngelheimJardiance$259$139,053130 claims
AstraZenecaFarxiga$801$74,61876 claims
MerckJanuvia$143$73,78868 claims
Lilly USA, LLCMounjaro, Humulin 70-30$171$56,28665 claims
NovartisEntresto$86$25,22525 claims
Johnson & JohnsonXarelto$28$14,35711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →